Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference

Alexza Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare

PR Newswire

MOUNTAIN VIEW, Calif., Nov. 21, 2013

MOUNTAIN VIEW, Calif., Nov. 21, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that the Company will participate in the
25^th Annual Piper Jaffray Healthcare Conference, being held in New York, NY,
on December 3 - 4, 2013. Thomas B. King, Alexza President and CEO, will
present at the conference. The Alexza corporate presentation will be Tuesday,
December 3, 2013 at 2:30 p.m. Eastern Time. The presentation will be webcast

To access the presentation via the Web, please go to the Alexza Investor
Relations tab at or at A replay of the webcast will be
available approximately 24 hours after the presentation and archived for 30

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions. Alexza's products are based on the
Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the
deep lung, providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.

ADASUVE (Staccato loxapine) is Alexza's first commercial product, which was
approved by the U.S. Food and Drug Administration in December 2012 and by the
European Commission in February 2013. Teva Pharmaceuticals USA, Inc. is
Alexza's commercial partner for ADASUVE in the U.S. Grupo Ferrer
Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe,
Latin America, Russia and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit For more
information about ADASUVE, please visit

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties. Any statement describing the
Company's expectations or beliefs is a forward-looking statement, as defined
in the Private Securities Litigation Reform Act of 1995, and should be
considered an at-risk statement. Such statements are subject to certain risks
and uncertainties, particularly those inherent in the process of developing
and commercializing drugs, including the ability of Alexza and our partners,
Teva and Ferrer, to effectively and profitably commercialize ADASUVE,
estimated product revenues and royalties associated with the sale of ADASUVE,
the adequacy of the Company's capital to support the Company's operations, and
the Company's ability to raise additional funds and the potential terms of
such potential financings. The Company's forward-looking statements also
involve assumptions that, if they prove incorrect, would cause its results to
differ materially from those expressed or implied by such forward-looking
statements. These and other risks concerning Alexza's business are described
in additional detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2012 and the Company's other Periodic and Current Reports
filed with the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the Company
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Contact: BCC Partners, Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662,
Press spacebar to pause and continue. Press esc to stop.